Welcome to our dedicated page for BRISTOL MYERS SQUIBB CO SEC filings (Ticker: CELG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BRISTOL MYERS SQUIBB CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BRISTOL MYERS SQUIBB CO's regulatory disclosures and financial reporting.
Bristol Myers Squibb Chief Executive Officer Christopher S. Boerner reported multiple equity compensation transactions involving common stock and share units. On 2026-03-10, he exercised or settled 71,537 market share and performance share units into common stock and had 21,229 shares withheld at $60.13 per share to cover tax obligations and exercise costs.
He also received new long-term incentives, including 104,490 market share units and 156,735 performance share units that vest or convert based on multi-year performance conditions and Board certification. After these transactions, Boerner held 21,451 shares of common stock directly and 125,439 shares indirectly through a trust, reflecting compensation-related awards and routine tax withholding rather than open-market trading.
Bristol Myers Squibb EVP and CFO David V. Elkins reported a series of equity compensation transactions involving company stock. He exercised derivative awards, converting 62,982 market share units and performance shares into common stock on March 10, 2026, as previously granted awards vested under performance-based plans. He also received new grants of 35,265 market share units and 52,898 performance share units that will vest in future years based on performance and Board certification. To cover tax obligations on these vestings, 16,114 shares of common stock were withheld at a price of $60.13 per share, which is a non-market tax payment rather than an open-market sale. Following these transactions, Elkins directly holds 189,248 shares of common stock and has an additional 291.17 shares held indirectly through the BMS Savings and Investment Program.
Bristol Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, cardiovascular and neuroscience, generating $48,194 million in revenues for the year ended December 31, 2025, roughly flat versus 2024 and up from 2023.
The business is anchored by growth brands such as Opdivo, Eliquis, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati and Cobenfy, supported by broad patent and regulatory exclusivity across the U.S., EU and Japan. Legacy products including Revlimid, Pomalyst, Sprycel and Abraxane face generic erosion in key markets.
The company invested heavily in innovation, with $10.0 billion of R&D expense in 2025 and a pipeline of more than 45 assets across small molecules, biologics, ADCs, CAR-T and radiopharmaceuticals. New and expanded manufacturing facilities for cell therapies and radiopharmaceuticals were brought online in the U.S. and Europe.
Regulatory and pricing pressures are intensifying. Specific products, including Eliquis and Pomalyst, are subject to government-set Medicare prices under the Inflation Reduction Act, and Orencia has been selected for future “negotiation.” A 2025 agreement with the U.S. government adds further concessions, including providing Eliquis free to Medicaid and offering substantial direct-to-patient discounts on several brands.
Bristol Myers Squibb executive Gregory Scott Meyers reported equity compensation activity involving restricted stock units and common shares. On February 1, 2026, 2,543 restricted stock units vested and converted into 2,543 shares of common stock at an exercise price of $0, reflecting previously granted awards that vest annually in four equal installments beginning on February 1, 2023.
On the same date, 833 common shares were withheld at a price of $55.05 to cover taxes due upon vesting of the restricted stock units. After these transactions, Meyers directly owned 21,428 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Benjamin Hickey reported routine equity compensation activity. On February 1, 2026, 10,079 restricted stock units vested, each converting into one share of common stock at an exercise price of $0.
To cover taxes on the vesting, 3,810 common shares were withheld at a price of $55.05 per share. After these transactions, Hickey directly owned 15,058 shares of Bristol Myers Squibb common stock and 10,079 restricted stock units remained outstanding, scheduled to vest in equal annual installments beginning February 1, 2025.
Bristol Myers Squibb director Phyllis R. Yale received 3,996.367 Deferred Share Units on February 1, 2026 at a reference price of $55.05 per unit. These derivative awards increase her holdings of Deferred Share Units to 43,326.695, all held directly.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when she ceases to be a director or at a future date she previously specified, and reflect deferred compensation and reinvested dividends under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Karen H. Vousden reported an award of derivative securities tied to company stock. On February 1, 2026, she acquired 3,996.367 Deferred Share Units at $55.05 each, bringing her total to 41,069.315 Deferred Share Units, held directly.
Each Deferred Share Unit converts into one share of Bristol Myers Squibb common stock upon settlement. These units become settleable when she ceases to be a director or at a future date she previously selected. The total includes deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II reported an automatic grant of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. After this award, he beneficially owns 67,882.504 Deferred Share Units in total.
Each Deferred Share Unit converts into one share of common stock when settled. These units become settleable when he ceases to be a director or on a future date he previously selected, and the total includes deferred compensation and reinvested dividends under the company’s deferred compensation plan for non-employee directors.
Bristol Myers Squibb director Derica W. Rice reported an award of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. This increased his holdings of Deferred Share Units to 39,324.809, which track common stock and are settled in shares later.
Each Deferred Share Unit converts into one share of common stock when he leaves the board or on a future date he previously selected. The holdings also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Paula A. Price reported receiving 3,996.367 Deferred Share Units on February 1, 2026 at an indicated value of $55.05 per unit. Following this award, she beneficially owns 25,498.163 Deferred Share Units, held directly.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when Price ceases to be a director or at a future date she previously specified, and include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.